Warren Mark L, Chaykin Louis B, Jabbour Serge, Sheikh-Ali Mae, Hansen Charlotte T, Nielsen Thor S S, Norwood Paul
Physicians East, Greenville, NC.
Meridien Research, Bradenton, FL.
Clin Diabetes. 2017 Apr;35(2):90-95. doi: 10.2337/cd15-0058.
Many patients with type 2 diabetes require high basal insulin doses, necessitating multiple injections, increasing patient burden, and resulting in reduced treatment adherence. This randomized, controlled, crossover trial compared the efficacy, safety, and patient-reported outcomes for a concentrated formulation of insulin degludec (200 units/mL) to those of insulin glargine in patients requiring high doses of basal insulin. By offering equivalent glycemic control while reducing the rate of confirmed hypoglycemia and the number of injections required for administration, insulin degludec 200 units/mL may be preferred by patients with type 2 diabetes who require high basal insulin doses.
许多2型糖尿病患者需要高剂量的基础胰岛素，这就需要多次注射，增加了患者负担，并导致治疗依从性降低。这项随机、对照、交叉试验比较了在需要高剂量基础胰岛素的患者中，德谷胰岛素浓缩制剂（200单位/毫升）与甘精胰岛素在疗效、安全性和患者报告结局方面的差异。通过提供同等的血糖控制，同时降低确诊低血糖的发生率和给药所需的注射次数，200单位/毫升的德谷胰岛素可能会受到需要高剂量基础胰岛素的2型糖尿病患者的青睐。
